Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002609 | 0.85 | EPHX2 (0.54) | EPHX2HSD11B1EPHX1THRBATM | |
| SCHEMBL19049362 | 0.84 | HSD11B1 (0.52) | EPHX2HSD11B1EPHX1THRBATM | |
| SCHEMBL17316270 | 0.83 | EPHX2 (0.68) | EPHX2EPHX1 | |
| SCHEMBL12039329 | 0.81 | DRD2 (0.50) | HSD11B1THRBATML3MBTL1 | |
| SCHEMBL19002258 | 0.81 | HSD11B1 (0.50) | EPHX2HSD11B1EPHX1THRBATM | |
| SCHEMBL20665186 | 0.81 | HSD11B1 (0.50) | EPHX2HSD11B1THRBATML3MBTL1 | |
| SCHEMBL17323937 | 0.81 | EPHX2 (0.57) | EPHX2HSD11B1EPHX1 | |
| SCHEMBL7788916 | 0.80 | SMYD3 (0.47) | HSD11B1EPHX1THRBATML3MBTL1 | |
| SCHEMBL18380884 | 0.80 | SMYD3 (0.47) | HSD11B1EPHX1THRBATML3MBTL1 | |
| SCHEMBL7470486 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | EPHX2 2625/4885HSD11B1 1215/4885EPHX1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.